| Literature DB >> 22949822 |
Hyung-In Moon1, Jai-Heon Lee1.
Abstract
To examine the neuroprotective effects of Glycine max, we tested its protection against the glutamate-induced toxicity in primary cortical cultured neurons. In order to clarify the neuroprotective mechanism(s) of this observed effect, isolation was performed to seek and identify active fractions and components. From such fractionation, two triterpene glycosides, 3-O-[α-l-rhamnopyranosyl(1-2)-β-d-glucopyranosyl(1-2)-β-d-glucuronopyranosyl]olean-12-en-3β,22β,24-triol (1) and 3-O-[β-d-glucopyranosyl(1-2)-β-d-galactopyranosyl(1-2)-β-d-glucuronopyranosyl]olean-12-en-3β,22β,24-triol (2) were isolated with the methanol extracts with of air-dried Glycine max. Among these compounds, compound 2 exhibited significant neuroprotective activities against glutamate-induced toxicity, exhibiting cell viability of about 50% at concentrations ranging from 0.1 μM to 10 μM. Therefore, the neuroprotective effect of Glycine max might be due to the inhibition of glutamate-induced toxicity by triterpene glycosides.Entities:
Keywords: Glycine max; glutamate-induced toxicity; neuroprotective; triterpene glycosides
Mesh:
Substances:
Year: 2012 PMID: 22949822 PMCID: PMC3431820 DOI: 10.3390/ijms13089642
Source DB: PubMed Journal: Int J Mol Sci ISSN: 1422-0067 Impact factor: 6.208
Figure 1Isolated compounds structure from Glycine max.
Neuroprotective effects of extract and fractions from Glycine max against glutamate induced toxicity in primary cultured rat cortical cells a.
| Dose | Cell Viability | ||
|---|---|---|---|
|
| |||
| 5 μg/mL | 25 μg/mL | 100 μg/mL | |
| Control | 100 | ||
| Glutamate-treated | 0 | ||
| MeOH extracts | 13.4 ± 0.3 | 38.5 ± 3.2 | 59.0 ± 3.6 |
| Chloroform fraction | - | - | 12.3 ± 1.3 |
| Ethyl acetate fraction | - | 21.4 ± 6.3 | 55.3 ± 5.7 |
| n-butanol fraction | - | - | 5.8 ± 1.3 |
| BB-1 subfraction | - | - | - |
| BB-2 subfraction | - | - | - |
| BB-3 subfraction | 15.6 ± 3.6 | 36.7 ± 3.7 | 43.5 ± 2.6 |
| BB-4 subfraction | - | - | 26.7 ± 8.9 |
| BB-5 subfraction | - | - | - |
Rat cortical cell cultures were incubated with test compounds for 1 h. The cultures were then exposed to 100 μM glutamate for 24 h. After the incubation, the cultures were assessed for the extent of neuronal damage;
Cell viability was measured by the LDH assay;
LDH released from control (0.1% DMSO concentration in culture) and glutamate-treated cultures were 11.7 ± 1.3 and 47.9 ± 4.0 units/mL, respectively;
Cell viability was calculated as 100 × (LDH released from glutamate-treated-LDH released from glutamate + test compound-treated)/(LDH released from glutamate-treated-LDH released from control). The values shown are the mean ± STD of three experiments (3–4 cultures per experiment). Results differ significantly from the glutamate-treated:
p < 0.05,
p < 0.01,
p < 0.001;
Glutamate-treated value differed significantly from the untreated control at the level of p < 0.001.
Neuroprotective effects of triterpene glycosides from Glycine max against glutamate induced toxicity in primary cultured rat cortical cells a.
| Dose | Cell Viability | ||
|---|---|---|---|
|
| |||
| 0.1 μM | 1 μM | 10 μM | |
| Control | 100 | ||
| Glutamate-treated | 0 | ||
| 14.2 ± 0.3 | 16.7 ± 1.2 | 21.4 ± 5.6 | |
| 16.7 ± 1.5 | 39.2 ± 1.5 | 71.5 ± 6.8 | |
| APV | 11.5 ± 1.4 | 26.5 ± 2.3 | 42.5 ± 3.7 |
| MK-801 | 51.4 ± 4.6 | 63.5 ± 5.8 | 78.4 ± 2.0 |
| CNQX | 23.5 ± 3.7 | 44.8 ± 3.5 | 53.2 ± 4.6 |
Rat cortical cell cultures were incubated with test compounds for 1 h. The cultures were then exposed to 100 μM glutamate for 24 h. After the incubation, the cultures were assessed for the extent of neuronal damage;
Cell viability was measured by the LDH assay;
LDH released from control (0.1% DMSO concentration in culture) and glutamate-treated cultures were 11.7 ± 1.3 and 47.9 ± 4.0 units/mL, respectively;
Cell viability was calculated as 100 × (LDH released from glutamate-treated-LDH released from glutamate + test compound-treated)/(LDH released from glutamate-treated-LDH released from control). The values shown are the mean ± STD of three experiments (3–4 cultures per experiment). Results differ significantly from the glutamate-treated:
p < 0.05,
p < 0.01,
p < 0.001;
Glutamate-treated value differed significantly from the untreated control at the level of p < 0.001;
APV: dl-2-amino-5-phosphonovaleric acid, a competitive NMDA receptor antagonist;
MK-801: dizocilpine maleate, a noncompetitive NMDA receptor antagonist;
CNQX: 6−cyan°-7-nitroquinoxaline-2,3-dione, non-NMDA receptor antagonist.